Medline (NASDAQ:MDLN) Releases Earnings Results

Posted by Brian Himes on Nov 6th, 2026

Medline (NASDAQ:MDLN – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12, FiscalAI reports. The business had revenue of $7.86 billion during the quarter. Medline had a return on equity of 8.22% and a net margin of 1.84%.

Here are the key takeaways from Medline’s conference call:

Positive Sentiment: Third-quarter net sales rose 10% to $7.9 billion, and Adjusted EBITDA increased 12% to $1.0 billion. Growth was broad-based, though EBITDA included an $81 million benefit from tariff refunds.
Positive Sentiment: Medline raised its 2026 organic sales growth outlook for the third consecutive quarter, to 10%–10.5%, while reaffirming Adjusted EBITDA guidance of $3.3 billion–$3.4 billion, expected near the midpoint.
Negative Sentiment: Management expects 2027 sales growth in the high single digits but EBITDA growth only in the low to mid-single digits, citing elevated inflation and investment in capacity, operations, and quality. It expects EBITDA growth to return to at least sales growth in 2028.
Positive Sentiment: Medline reported strong customer signings and said it remains on track for its $1 billion 2026 goal; it is also expanding distribution capacity with four facilities planned or underway and progressing with its first Canadian Prime Vendor rollout.
Negative Sentiment: The Global Quality Action Plan is a multi-year effort involving third-party assessments and ongoing investment and remediation. Medline is exiting its roughly $60 million home-care-bed business, and management acknowledged other issues could emerge as it assesses its network.

Medline Price Performance

Shares of MDLN stock traded down $0.12 during mid-day trading on Friday, hitting $39.64. 6,376,411 shares of the stock were exchanged, compared to its average volume of 7,768,861. Medline has a 52-week low of $31.37 and a 52-week high of $50.88. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66. The company has a market cap of $52.11 billion and a PE ratio of 90.09. The firm has a fifty day moving average of $34.68 and a 200 day moving average of $39.51.

Insider Buying and Selling at Medline

In related news, major shareholder Private Ltd Gic sold 2,570,999 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the transaction, the insider owned 20,231,483 shares of the company’s stock, valued at approximately $715,182,924.05. This represents a 11.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 7,948,676 shares of company stock valued at $281,805,137. 0.81% of the stock is owned by insiders.

Institutional Trading of Medline

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC lifted its stake in shares of Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after buying an additional 254 shares in the last quarter. Covestor Ltd boosted its position in Medline by 31.8% during the third quarter. Covestor Ltd now owns 1,953 shares of the company’s stock worth $68,000 after acquiring an additional 471 shares during the last quarter. NewEdge Advisors LLC grew its stake in Medline by 100.0% during the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 475 shares in the last quarter. Allworth Financial LP grew its stake in Medline by 86.2% during the 2nd quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock valued at $41,000 after acquiring an additional 487 shares in the last quarter. Finally, Whipplewood Advisors LLC purchased a new stake in Medline during the 1st quarter valued at about $30,000.

Medline News Summary

Here are the key news stories impacting Medline this week:

Positive Sentiment: Medline reported Q3 earnings per share of $0.44, beating the $0.32 consensus estimate, with revenue of $7.86 billion. The earnings beat was cited as the reason shares gapped up. Medline Shares Gap Up Following Strong Earnings
Positive Sentiment: Several firms raised their price targets and maintained bullish ratings: UBS lifted its target to $49, Citi to $47, and Leerink Partners to $46. BTIG reaffirmed its Buy rating and $55 target; Barclays also issued a Buy rating. The cluster of positive calls may bolster investor confidence. Read More. · Read More. · Read More. · Read More. · Read More.
Positive Sentiment: Medline plans to raise prices in 2027 to help offset inflationary pressures. If implemented without materially weakening demand, the increases could support margins. Medline plans price increases and reports Q3 results
Neutral Sentiment: The planned price increases are intended to counter inflation, but their eventual benefit will depend on cost trends and customer response.

Wall Street Analyst Weigh In

Several analysts recently commented on MDLN shares. Truist Financial dropped their target price on Medline from $56.00 to $47.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft set a $37.00 price target on Medline and gave the company a “hold” rating in a report on Thursday, August 6th. Weiss Ratings lowered Medline from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Royal Bank Of Canada dropped their price objective on shares of Medline from $53.00 to $46.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, Barclays dropped their price objective on shares of Medline from $45.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, October 9th. Twenty-three analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.08.

View Our Latest Stock Analysis on MDLN

About Medline

(Get Free Report)

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.